VISTAGEN THERAPEUTICS INC (VTGN) Fundamental Analysis & Valuation

NASDAQ:VTGN • US92840H4002

Current stock price

0.5866 USD
-0.01 (-2.33%)
At close:
0.59 USD
+0 (+0.58%)
After Hours:

This VTGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VTGN Profitability Analysis

1.1 Basic Checks

  • VTGN had negative earnings in the past year.
  • VTGN had a negative operating cash flow in the past year.
  • VTGN had negative earnings in each of the past 5 years.
  • In the past 5 years VTGN always reported negative operating cash flow.
VTGN Yearly Net Income VS EBIT VS OCF VS FCFVTGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of VTGN (-79.04%) is worse than 66.92% of its industry peers.
  • VTGN has a Return On Equity (-100.98%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.04%
ROE -100.98%
ROIC N/A
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
VTGN Yearly ROA, ROE, ROICVTGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VTGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTGN Yearly Profit, Operating, Gross MarginsVTGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10K -10K 20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VTGN Health Analysis

2.1 Basic Checks

  • VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VTGN has been increased compared to 1 year ago.
  • The number of shares outstanding for VTGN has been increased compared to 5 years ago.
  • VTGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VTGN Yearly Shares OutstandingVTGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
VTGN Yearly Total Debt VS Total AssetsVTGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -10.85, we must say that VTGN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of VTGN (-10.85) is worse than 74.47% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that VTGN is not too dependend on debt financing.
  • The Debt to Equity ratio of VTGN (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -10.85
ROIC/WACCN/A
WACC9.21%
VTGN Yearly LT Debt VS Equity VS FCFVTGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • VTGN has a Current Ratio of 4.67. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VTGN (4.67) is comparable to the rest of the industry.
  • A Quick Ratio of 4.67 indicates that VTGN has no problem at all paying its short term obligations.
  • VTGN has a Quick ratio (4.67) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.67
Quick Ratio 4.67
VTGN Yearly Current Assets VS Current LiabilitesVTGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VTGN Growth Analysis

3.1 Past

  • The earnings per share for VTGN have decreased strongly by -27.84% in the last year.
  • Looking at the last year, VTGN shows a very negative growth in Revenue. The Revenue has decreased by -54.32% in the last year.
  • Measured over the past years, VTGN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.07% on average per year.
EPS 1Y (TTM)-27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.17%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%29.49%

3.2 Future

  • Based on estimates for the next years, VTGN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.29% on average per year.
  • VTGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 235.72% yearly.
EPS Next Y-9.24%
EPS Next 2Y15.19%
EPS Next 3Y1.99%
EPS Next 5Y26.29%
Revenue Next Year50.58%
Revenue Next 2Y161.46%
Revenue Next 3Y466.75%
Revenue Next 5Y235.72%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VTGN Yearly Revenue VS EstimatesVTGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 200M 400M 600M 800M 1B
VTGN Yearly EPS VS EstimatesVTGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

0

4. VTGN Valuation Analysis

4.1 Price/Earnings Ratio

  • VTGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VTGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTGN Price Earnings VS Forward Price EarningsVTGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTGN Per share dataVTGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.19%
EPS Next 3Y1.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VTGN Dividend Analysis

5.1 Amount

  • VTGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VTGN Fundamentals: All Metrics, Ratios and Statistics

VISTAGEN THERAPEUTICS INC

NASDAQ:VTGN (4/2/2026, 8:00:49 PM)

After market: 0.59 +0 (+0.58%)

0.5866

-0.01 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)06-15
Inst Owners25.84%
Inst Owner Change-40.9%
Ins Owners0.2%
Ins Owner Change1.64%
Market Cap23.24M
Revenue(TTM)486.00K
Net Income(TTM)-51.42M
Analysts50
Price Target3.8 (547.8%)
Short Float %3.55%
Short Ratio1.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1%
Min EPS beat(2)-11.22%
Max EPS beat(2)9.22%
EPS beat(4)3
Avg EPS beat(4)3.84%
Min EPS beat(4)-11.22%
Max EPS beat(4)14.73%
EPS beat(8)6
Avg EPS beat(8)8.63%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.44%
Min Revenue beat(2)-18.84%
Max Revenue beat(2)3.95%
Revenue beat(4)1
Avg Revenue beat(4)-43.35%
Min Revenue beat(4)-95.33%
Max Revenue beat(4)3.95%
Revenue beat(8)2
Avg Revenue beat(8)-30.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-48.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.01%
EPS NY rev (1m)5.12%
EPS NY rev (3m)2.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.18%
Revenue NY rev (1m)15.76%
Revenue NY rev (3m)45.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.82
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0.01
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.04%
ROE -100.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.81%
Cap/Sales 49.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.67
Quick Ratio 4.67
Altman-Z -10.85
F-Score1
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)112.3%
Cap/Depr(5y)140.71%
Cap/Sales(3y)45.45%
Cap/Sales(5y)36.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.17%
EPS Next Y-9.24%
EPS Next 2Y15.19%
EPS Next 3Y1.99%
EPS Next 5Y26.29%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%29.49%
Revenue Next Year50.58%
Revenue Next 2Y161.46%
Revenue Next 3Y466.75%
Revenue Next 5Y235.72%
EBIT growth 1Y-69.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-131.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-131.06%
OCF growth 3YN/A
OCF growth 5YN/A

VISTAGEN THERAPEUTICS INC / VTGN Fundamental Analysis FAQ

What is the fundamental rating for VTGN stock?

ChartMill assigns a fundamental rating of 2 / 10 to VTGN.


Can you provide the valuation status for VISTAGEN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to VISTAGEN THERAPEUTICS INC (VTGN). This can be considered as Overvalued.


What is the profitability of VTGN stock?

VISTAGEN THERAPEUTICS INC (VTGN) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for VTGN stock?

The Earnings per Share (EPS) of VISTAGEN THERAPEUTICS INC (VTGN) is expected to decline by -9.24% in the next year.